Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key? [0.03%]
PD-1检查点抑制剂治疗黑色素瘤及其他疾病的有效性：周边T细胞表型是关键因素吗？
Katie R Flaherty,Stephanie Kucykowicz,Johannes Schroth et al.
Katie R Flaherty et al.
Immunotherapy treatment strategies have proven effective in a limited portion of patients, where identifying responders from non-responders to treatment remains a challenge. While some indications can be drawn from invasive biopsies, we nee...
Melissa M Christodoulidou,Neil A Mabbott
Melissa M Christodoulidou
The Mpox virus (MPXV) is endemic in certain countries in Central and West Africa, where several mammalian species, especially rodents, are natural reservoirs. However, the MPXV can infect nonhuman primates and cause zoonotic infections in h...
[This corrects the article DOI: 10.1093/immadv/ltac022.]. © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society fo...
Published Erratum
Immunotherapy advances. 2023 Oct 12;3(1):ltad017. DOI:10.1093/immadv/ltad017 2023
Correction to: Blockade of innate inflammatory cytokines TNFα, IL-1β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression [0.03%]
Correction to: 阻止天然炎症细胞因子 TNFα、IL-1β 或 IL-6 可克服病毒疗法引起的肿瘤平衡以促进肿瘤消退
[This corrects the article DOI: 10.1093/immadv/ltad011.]. © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society fo...
Published Erratum
Immunotherapy advances. 2023 Oct 12;3(1):ltad019. DOI:10.1093/immadv/ltad019 2023
Correction to: TIM-3: a tumor-associated antigen beyond checkpoint inhibition? [0.03%]
Correction to: TIM-3：超越检查点抑制的肿瘤相关抗原？
[This corrects the article DOI: 10.1093/immadv/ltac021.]. © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society fo...
Published Erratum
Immunotherapy advances. 2023 Oct 12;3(1):ltad018. DOI:10.1093/immadv/ltad018 2023
Lars Klareskog,Lars Alfredsson
Lars Klareskog
Whether a yet chronic and not curable disease like rheumatoid arthritis (RA) can be subject to prevention or whether available resources should be focused on treatment is a classical dilemma. Similar to the case in most other chronic diseas...
Walter Bodmer
Walter Bodmer
The discovery of the history of the HLA system is reviewed from the earliest attempts at cancer transfers between mice, through the discovery of the mouse H-2 system on mouse red blood cells, the discovery of HLA class II and II antigens by...
Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood [0.03%]
免疫抑制药物耐药性盔甲T细胞在全血中对抗HBV相关循环肝癌细胞的裂解效率研究
Meiyin Lin,Sebastian Chakrit Bhakdi,Damien Tan et al.
Meiyin Lin et al.
Recurrence of hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) after liver transplant (LT) is mediated by circulating tumour cells (CTCs) and exacerbated by the immunosuppressants required to prevent graft rejection. To circumve...
Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment [0.03%]
双特异性T细胞衔接器癌症治疗的联合疗法优化
Winston M Zhu,Mark R Middleton
Winston M Zhu
Bispecific T-cell engagers (BiTEs) redirect endogenous T-cell populations to cells expressing tumour-associated antigens to induce tumour cell killing. This inherently relies upon a cytotoxic T-cell population that is able to be recruited. ...
Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration [0.03%]
自身免疫性疾病耐受性树突状细胞治疗的挑战：给药途径的影响
María José Mansilla,Catharien M U Hilkens,Eva M Martínez-Cáceres
María José Mansilla
Tolerogenic dendritic cells (tolDCs) are a promising strategy to treat autoimmune diseases since they have the potential to re-educate and modulate pathological immune responses in an antigen-specific manner and, therefore, have minimal adv...